Tobias Tix

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: June 18, 2026

From Clinical Laboratory Results to REDCap: An Automated Workflow for Longitudinal CAR-T Research Data.

From Clinical Laboratory Results to REDCap: An Automated Workflow for Longitudinal CAR-T Research Data.

Journal: Studies in health technology and informatics

Published: May 23, 2026

Modern Management of Mantle Cell Lymphoma.

Modern Management of Mantle Cell Lymphoma.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 07, 2026

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

Journal: Leukemia

Published: March 18, 2026

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Journal: Nature medicine

Published: January 27, 2026

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients.

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients.

Journal: Blood advances

Published: January 08, 2026

Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.

Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.

Journal: Blood advances

Published: January 08, 2026

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Journal: Lancet (London, England)

Published: December 23, 2025

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.

Journal: EJHaem

Published: November 12, 2025

Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.

Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.

Journal: Blood

Published: September 03, 2025

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.

Journal: Blood

Published: September 03, 2025

Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?

Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?

Journal: The Lancet. Haematology

Published: May 18, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026